Amgen
The primary objective of this trial is to evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational product early.
Inclusion Criteria: \- Participant has provided informed consent/assent prior to initiation of any trial specific activities/procedures. OR Participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent, and the participant has provided written assent based on local regulations and/or guidelines prior to any trial-specific activities/procedures being initiated. \- Participant was randomized to the romosozumab arm and completed Trial 20200105 through the Month 15 Visit, regardless of whether they received in…
Participants are recommended to receive Vitamin D supplements as standard of care treatment, per investigator discretion and local guidance.
Participants are recommended to receive Calcium supplements as standard of care treatment, per investigator discretion and local guidance.
Arctuva estimate
Verify or correct the compensation shown for this listing.